Data Readout

Kodiak's DAYBREAK trial nears wet AMD readout against Aflibercept

Enrollment is complete and the primary completion date has passed; topline data testing whether Zenkuda and KSI-501 match Aflibercept on vision gain are expected in September 2026.

By AppliedXLJuly 14, 2026Trial NCT06556368

Executive Summary

Kodiak Sciences has finished enrolling its pivotal wet AMD study and is heading toward a readout that will test its antibody biopolymer conjugate platform against the field's established anti-VEGF standard.
The trial's completion date moved back over the course of two amendments, stretching the expected readout window by months without any change to the number of patients enrolled.
A positive result would support Kodiak's plan to expand toward a multi-indication regulatory filing, building on separate positive data the company has already reported in a related retinal disease.
The comparator is a monoclonal antibody with an established efficacy record in wet AMD, and no same-drug precedent yet exists for the two Kodiak candidates in this specific pairing, leaving the readout as the first read on how they compare in a randomized, active-controlled setting.

The catalyst

DAYBREAK (NCT06556368) is a Phase 3, randomized, active-comparator trial testing tarcocimab tedromer and tabirafusp tedromer against aflibercept in patients with neovascular age-related macular degeneration. The primary endpoint is best corrected visual acuity (BCVA), measured in a population with baseline ETDRS scores between 25 and 78 letters. Kodiak Sciences said in a March 31, 2026 disclosure that it had completed enrollment with approximately 690 subjects and that topline data were expected in September 2026. NCT06556368+1

Probability of Success

Endpoint Met91%

Completes97%

Clinical Significance50%

Regulatory31%

Trial context: timing shift

The trial's primary completion date moved twice. It shifted from January 2026 to April 2026 in a February 2025 registry update, then to August 2026 in an October 2025 update that coincided with the trial's move from Recruiting to Active, not recruiting status. Enrollment held at the original target of 675 patients across both changes, which the operational model reads as typical and not a signal of trouble on its own. The registered primary completion date of August 2026 sits ahead of the September 2026 readout window the company has guided to in its disclosures. NCT06556368+1

The endpoint bar

Aflibercept is the active comparator arm in DAYBREAK, positioning the trial as a test of whether Kodiak's molecules can reproduce the visual-acuity gains associated with an approved, mechanistically validated anti-VEGF therapy rather than beat a placebo or sham control. Kodiak's own retinal disease program has already produced a positive readout this year: the company reported in the same disclosure that its GLOW2 Phase 3 study showed tarcocimab tedromer beat sham on diabetic retinopathy severity score improvement, with 62.5% of treated patients achieving a two-step improvement versus 3.3% on sham (p<0.0001). That result does not establish what DAYBREAK will show in wet AMD, a different disease population measured on a different endpoint, but it demonstrates the same molecule has produced a differentiated effect against a control arm in at least one registrational study. NCT06556368+1

Competitive frame

Direct comparators sharing the same VEGF-A target and a comparable modality include ranibizumab, a monoclonal antibody in Phase 3 testing sponsored by Hoffmann-La Roche, and gene-therapy candidates from AbbVie and 4D Molecular Therapeutics that aim to reduce injection frequency rather than match BCVA outcomes head-to-head. No trial in the competitive set shares both the Zenkuda/KSI-501 pairing and this exact comparator design, so DAYBREAK is the first randomized read on how Kodiak's antibody biopolymer conjugate and bispecific candidate perform against aflibercept specifically, rather than a replication of a prior head-to-head result.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.